Green Journals

Year	A	B
2026	✓	✓
2025	✓	✓
2024	✓	✓
2023	✓	✓
2021/2022	✓	✓
2020	✓	✓
2019	✓	✓
2018	✓

Drugging the luminal axis end to end: A review of next-generation endocrine and targeted therapies in HR + /HER2- metastatic breast cancer

Aldo Caltavituro, Antonio Giordano, Carmine De Angelis et al.

2026-12 Vol. 249 Pages 117794

DOI: 10.1016/j.ejca.2026.117794

What does addressing cancer inequalities really mean? Five principles that can drive global action

Matti Aapro, Nicolò Matteo Luca Battisti, Joseph Gligorov et al.

2026-12 Vol. 249 Pages 117782

DOI: 10.1016/j.ejca.2026.117782

Outcomes of CD20-targeting CAR T-cell therapy in patients with advanced melanoma: MB-CART20.1 Melanoma phase I trial

Hyatt Balke-Want, Sebastian Theurich, Philipp Gödel et al.

2026-12 Vol. 249 Pages 117780

DOI: 10.1016/j.ejca.2026.117780

A new era in anti-RAS therapy: Unique challenges and opportunities for radiotherapy clinical trials

Susannah G. Ellsworth, Timothée Olivier

2026-12 Vol. 249 Pages 117790

DOI: 10.1016/j.ejca.2026.117790

Computational image features of immune architecture reveal molecular patterns associated with outcome and risk of recurrence in microsatellite-stable or MSI-low colon cancers

Bolin Song, Himanshu Maurya, Sirvan Khalighi et al.

2026-12 Vol. 249 Pages 117810

DOI: 10.1016/j.ejca.2026.117810

Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM)

Rachel Galot, Christophe Le Tourneau, Lisa Licitra et al.

2026-12 Vol. 249 Pages 117791

DOI: 10.1016/j.ejca.2026.117791

Response to letter Re: Diagnostic testing accuracy of DNA methylation tests for detection of high-grade cervical intraepithelial neoplasia and cervical cancer: A systematic review and meta-analysis

Laura Burney Ellis, Sarah J. Bowden, Jack Tighe et al.

2026-12 Vol. 249 Pages 117779

DOI: 10.1016/j.ejca.2026.117779

Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?

Patrick Neven, Francois Duhoux, Philippe Aftimos et al.

2026-12 Vol. 249 Pages 117808

DOI: 10.1016/j.ejca.2026.117808

Efficacy and safety of chimeric antigen receptor T-cell therapy versus standard treatment in hemato-oncology: A systematic review and meta-analysis

Ádám Szilágyi, Petra Varga, Gergely Agócs et al.

2026-12 Vol. 249 Pages 117820

DOI: 10.1016/j.ejca.2026.117820

Circulating tumor DNA-guided therapeutic strategies for metastatic colorectal cancer patients with multiple small pulmonary-limited nodules: A prospective cohort study

Jinjia Chang, Yaqi Li, Shaobo Mo et al.

2026-12 Vol. 249 Pages 117793

DOI: 10.1016/j.ejca.2026.117793

Journal Report

Journal Information

Classification History

Recent Articles